Literature DB >> 29846841

An Update on Autoinflammatory Diseases: Relopathies.

Annemarie Steiner1,2, Cassandra R Harapas3, Seth L Masters4,5, Sophia Davidson3.   

Abstract

PURPOSE OF REVIEW: The nuclear factor κB (NF-κB) pathway is tightly regulated through multiple posttranslational mechanisms including ubiquitination. Mutations in these regulatory pathways can cause disease and are the focus of this review. RECENT
FINDINGS: The linear ubiquitin chain assembly complex (LUBAC) is a trimer made up of HOIL-1L, SHARPIN, and the catalytic subunit HOIP. Loss of function mutations in HOIL-1L and HOIP result in largely overlapping phenotypes, characterized by multi-organ autoinflammation, immunodeficiency, and amylopectinosis. Interestingly, patient fibroblasts exhibited diminished IL-1β- and TNF-induced NF-κB activation, yet monocytes were hyper-responsive to IL-1β, hinting at cell type or target specific roles of LUBAC-mediated ubiquitination. Ubiquitin-driven signaling is counterbalanced by deubiquitinase enzymes (DUBs), such as OTULIN and A20. Hypomorphic mutations in OTULIN result in elevated NF-κB signaling causing an autoinflammatory syndrome. Similarly, patients with high-penetrance heterozygous mutations in the gene encoding A20 (haploinsufficiency of A20 (HA20)) display excessive ubiquitination and increased activity of NF-κB and of NLRP3 inflammasome activation. HA20 patients present with Behçet-like characteristics or an autoimmune lymphoproliferative syndrome (ALPS)-like phenotype, indicating diverse protein functions. This review summarizes recent discoveries in the field of NF-kB-related autoinflammatory diseases (relopathies) within the past 3 years and points to several questions that still remain unanswered.

Entities:  

Keywords:  A20; Autoinflammatory disease; LUBAC; NF-kB; OTULIN; Relopathy

Mesh:

Substances:

Year:  2018        PMID: 29846841     DOI: 10.1007/s11926-018-0749-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  42 in total

Review 1.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

2.  Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction.

Authors:  Tobias L Haas; Christoph H Emmerich; Björn Gerlach; Anna C Schmukle; Stefanie M Cordier; Eva Rieser; Rebecca Feltham; James Vince; Uwe Warnken; Till Wenger; Ronald Koschny; David Komander; John Silke; Henning Walczak
Journal:  Mol Cell       Date:  2009-12-11       Impact factor: 17.970

3.  Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway.

Authors:  G Takaesu; J Ninomiya-Tsuji; S Kishida; X Li; G R Stark; K Matsumoto
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 4.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

5.  Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation.

Authors:  Fuminori Tokunaga; Hiroshi Nishimasu; Ryuichiro Ishitani; Eiji Goto; Takuya Noguchi; Kazuhiro Mio; Kiyoko Kamei; Averil Ma; Kazuhiro Iwai; Osamu Nureki
Journal:  EMBO J       Date:  2012-08-28       Impact factor: 11.598

6.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Honglin Zhou; Michael Eby; L Aravind; Somasekar Seshagiri; Ping Wu; Christian Wiesmann; Rohan Baker; David L Boone; Averil Ma; Eugene V Koonin; Vishva M Dixit
Journal:  Nature       Date:  2004-07-18       Impact factor: 49.962

7.  Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells.

Authors:  Yoshiteru Sasaki; Soichi Sano; Masaki Nakahara; Shigeo Murata; Kohei Kometani; Yuichi Aiba; Shinji Sakamoto; Yoshihiro Watanabe; Keiji Tanaka; Tomohiro Kurosaki; Kazuhiro Iwai
Journal:  EMBO J       Date:  2013-08-13       Impact factor: 11.598

8.  Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation.

Authors:  Simin Rahighi; Fumiyo Ikeda; Masato Kawasaki; Masato Akutsu; Nobuhiro Suzuki; Ryuichi Kato; Tobias Kensche; Tamami Uejima; Stuart Bloor; David Komander; Felix Randow; Soichi Wakatsuki; Ivan Dikic
Journal:  Cell       Date:  2009-03-20       Impact factor: 41.582

9.  Molecular basis and regulation of OTULIN-LUBAC interaction.

Authors:  Paul R Elliott; Sofie V Nielsen; Paola Marco-Casanova; Berthe Katrine Fiil; Kirstin Keusekotten; Niels Mailand; Stefan M V Freund; Mads Gyrd-Hansen; David Komander
Journal:  Mol Cell       Date:  2014-04-10       Impact factor: 19.328

10.  Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains.

Authors:  Christoph H Emmerich; Alban Ordureau; Sam Strickson; J Simon C Arthur; Patrick G A Pedrioli; David Komander; Philip Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-28       Impact factor: 11.205

View more
  11 in total

Review 1.  Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.

Authors:  Peter A Nigrovic; Pui Y Lee; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2020-11       Impact factor: 10.793

Review 2.  Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.

Authors:  Giulia Di Donato; Debora Mariarita d'Angelo; Luciana Breda; Francesco Chiarelli
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

3.  ALPK1 Gene Mutations Drive Autoinflammation with Ectodermal Dysplasia and Progressive Vision Loss.

Authors:  Yvan Jamilloux; Thibaud Mathis; Olivier Grunewald; Hélène Dollfuss; Thomas Henry; Pascal Sève; Isabelle Meunier
Journal:  J Clin Immunol       Date:  2021-06-22       Impact factor: 8.542

Review 4.  Biochemistry of Autoinflammatory Diseases: Catalyzing Monogenic Disease.

Authors:  David B Beck; Ivona Aksentijevich
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

Review 5.  Hereditary systemic autoinflammatory diseases and Schnitzler's syndrome.

Authors:  Mark Kacar; Shelly Pathak; Sinisa Savic
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

Review 6.  Notch Signaling Regulation in Autoinflammatory Diseases.

Authors:  Rossella Gratton; Paola Maura Tricarico; Adamo Pio d'Adamo; Anna Monica Bianco; Ronald Moura; Almerinda Agrelli; Lucas Brandão; Luisa Zupin; Sergio Crovella
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

7.  LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages.

Authors:  Ommar Omarjee; Anne-Laure Mathieu; Gaëlle Quiniou; Marion Moreews; Michelle Ainouze; Cécile Frachette; Isabelle Melki; Cécile Dumaine; Mathieu Gerfaud-Valentin; Agnès Duquesne; Tilmann Kallinich; Eda Tahir Turanli; Christophe Malcus; Sébastien Viel; Rémi Pescarmona; Sophie Georgin-Lavialle; Yvan Jamilloux; Jean-Paul Larbre; Guillaume Sarrabay; Flora Magnotti; Gillian I Rice; Francoise Bleicher; Jonathan Reboulet; Samir Merabet; Thomas Henry; Yanick J Crow; Mathias Faure; Thierry Walzer; Alexandre Belot
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

Review 8.  Understanding Behçet's Disease in the Context of Innate Immunity Activation.

Authors:  Sandro F Perazzio; Luis E C Andrade; Alexandre W S de Souza
Journal:  Front Immunol       Date:  2020-10-20       Impact factor: 7.561

9.  Selenium-Enriched Yeast Relieves Hexavalent Chromium Toxicity by Inhibiting NF-κB Signaling Pathway in Broiler Spleens.

Authors:  Yanbing Zhao; Dezheng Hao; Huan Zhang; Jingqiu Wang; Ci Liu
Journal:  Animals (Basel)       Date:  2022-01-08       Impact factor: 2.752

Review 10.  The everchanging framework of autoinflammation.

Authors:  Raffaele Manna; Donato Rigante
Journal:  Intern Emerg Med       Date:  2021-05-17       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.